PATENT CLAIM ANALYSIS

Application Number: 16004077
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["436", "501000"]

Abstract:
The present invention relates to a compound selectively binding to a sensory receptor or selectively altering the expression of a sensory receptor for use in a method for treating or preventing a disease associated with a pathologic cellular cytotoxic T cell (CTL) response. Further, the invention relates to means for detecting a sensory receptor for use in a method for diagnosing cellular resistance against CTL response in a patient. The invention further embraces a method for determining the resistance of a cell against a CTL response in vitro and to a method for identifying agents that influence the response of cells to CTLs.

Claim (Index 27):
The method according to  claim 26 , wherein step (ii) comprises contacting the cell with\n (a) at least one compound selectively binding to the at least one sensory receptor, preferably wherein said compound is labeled, in particular fluorescently labeled, labeled by a contrast agent, spin-labeled and/or radioactively labeled, in particular wherein said compound is an antibody or an sensory receptor-binding fragment thereof; and/or (b) at least one antagonist of the at least one sensory receptor and/or of the at least polypeptide involved in cell signaling of a sensory receptor, in particular wherein said antagonist is interfering RNA, in particular small interfering ribonucleic acid (siRNA) or small hairpin RNA (shRNA), complementary to said sensory receptor, co-incubating the cell contacted with the at least one antagonist with at least one CTL, and subsequently determining the CTL activity, preferably determining the CTL activity by one of the following:\n (i) by determining the viability of the cell co-incubated with the at least one CTL and comparing the viability with that of a sample comprising a comparable cell and CTLs not treated by said antagonist, or \n (ii) by determining the excretion of polypeptides typical for CTL activity, such as one or more interferon(s) (IFN), one or more interleukin(s) (IL) and/or one or more tumor necrosis factor(s) (TNF), and comparing the results with that of a sample comprising a comparable cell and CTLs not treated by said antagonist.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 94.0
- Lexical Diversity: 2.01852
- Patent Class: 436.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14914585', '13819940', '13126039', '13321812', '15981142']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.647876022384277
- 35 USC 102 Novelty (BERT): 0.6114340085848251
- Combined Prediction Score: 0.6442318210043317
- Mean Citation Score: 353.8247340000001
- Max Citation Score: 727.0481599999997
- Similarity Product: 494.31600692306506

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test